AUSTIN, Texas—Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc. (NASDAQ:), has recently offloaded a significant amount of his shares in the company. This decision comes amid Natera’s impressive stock performance, boasting a 159% return over the past year and reaching a market capitalization of $22.12 billion. As disclosed in a filing with the Securities and Exchange Commission, Moshkevich sold 24,861 shares of Natera’s common stock on January 22, 2025, earning about $4.1 million from the transactions, which occurred at prices between $164.95 and $171.95 per share.
After the sales, Moshkevich still holds 140,684 shares in the company. The filing indicates that these sales were made to fulfill tax withholding requirements tied to the vesting of restricted stock units, following a pre-established trading plan. Analysis from InvestingPro highlights Natera’s solid financial health, reflected in a ‘GOOD’ health score and strong liquidity, as shown by a current ratio of 4.39. For a comprehensive look at insider trading activities and detailed financial analyses, investors can explore the Pro Research Report, which is available exclusively on InvestingPro.
In other recent developments, Natera Inc has been making significant strides in the sector. Barclays (LON:) has upgraded the company’s stock to Overweight with a target price of $200, citing Natera’s expansion into new markets and an impressive revenue surge of nearly 55% over the past year. Analyst Luke Sergott noted Natera’s transition from its initial focus on non-NGS-based NIPT to becoming a key player in the NIPT market alongside its foray into NGS-based Oncology and Organ Health testing.
Natera is also broadening its patent infringement case against NeoGenomics (NASDAQ:) related to the RaDaR assay. Despite experiencing a setback in a false advertising lawsuit against Guardant Health (NASDAQ:), Natera intends to seek a court decision to overturn that ruling. Additionally, an agreement with Dr. Rabinowitz, the Executive Chairman, has been revised to allow him to continue in his role under specific conditions.
TD Cowen has reaffirmed a Buy rating on Natera’s shares, increasing the price target from $175 to $195, demonstrating confidence in the company’s outlook. Likewise, Baird and Jefferies have also maintained optimistic ratings on Natera’s stock while raising their price targets.
Finally, Natera reported record Q3 revenue of $439.8 million, reflecting a 64% year-over-year increase, and conducted 137,000 oncology tests. These recent updates provide valuable insights into Natera’s current standing and future potential for investors.
This article was generated with the support of AI and reviewed by an editor. For more information refer to our T&C.
